By Mill Chart
Last update: Sep 24, 2024
Uncover the potential of ADMA BIOLOGICS INC (NASDAQ:ADMA), a growth stock that our stock screener found to be reasonably priced. NASDAQ:ADMA is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation. We'll examine each aspect in detail.
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:ADMA was assigned a score of 7 for growth:
ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:ADMA scores a 6 out of 10:
ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NASDAQ:ADMA was assigned a score of 7 for health:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:ADMA, the assigned 5 is a significant indicator of profitability:
Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.
For an up to date full fundamental analysis you can check the fundamental report of ADMA
This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
20.81
-0.79 (-3.66%)
Find more stocks in the Stock Screener
ADMA Biologics (NASDAQ:ADMA) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a candidate for momentum investors.
ADMA Biologics (NASDAQ:ADMA) shows strong growth fundamentals and a technical breakout setup, making it a stock to watch in the biotech sector.
ADMA Biologics (NASDAQ:ADMA) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has outperformed peers and may present a breakout opportunity.
ADMA Biologics (NASDAQ:ADMA) shows strong growth, reasonable valuation, and solid financial health, making it an attractive candidate for investors seeking affordable growth stocks in the biotech sector.